Nephrolux® Human Breath Ammonia Analyzers represent a groundbreaking advancement in noninvasive diagnostics for kidney disorders and malfunctions. Developed by Pranalytica, Inc., these sensors offer a swift and reliable alternative to traditional blood sampling methods. When kidney function is compromised, levels of urea nitrogen and creatinine in the blood increase, necessitating timely and accurate diagnostics. Nephrolux® addresses this need by measuring ammonia levels in exhaled breath, which correlate directly with blood urea nitrogen and creatinine concentrations. This innovative approach eliminates the need for invasive blood draws and lengthy lab processing times, delivering results in just two minutes.

The noninvasive nature of the Nephrolux® test allows for frequent administration, particularly beneficial for patients undergoing dialysis. By providing real-time data, healthcare providers can ensure optimal dialysis treatment, adjusting as necessary based on immediate results. This capability is crucial for managing patients with terminal kidney failure, as it supports continuous monitoring and timely intervention.

Beyond kidney diagnostics, the Nephrolux® has potential applications in monitoring abnormal pregnancy conditions, such as preeclampsia. By tracking breath ammonia concentrations, early warnings of potential complications can be identified, enabling proactive management and improved maternal and fetal outcomes.

For more information or inquiries, please contact Mr. Frank McGuire at (310) 458-4493 or via email at fxmcguire@pranalytica.com. Pranalytica, Inc. is proud to be an ISO 9001 Certified Company, committed to delivering high-quality, innovative solutions in medical diagnostics.